Simon Vanveggel

4.7k total citations
43 papers, 1.8k citations indexed

About

Simon Vanveggel is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Simon Vanveggel has authored 43 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Infectious Diseases, 32 papers in Virology and 7 papers in Epidemiology. Recurrent topics in Simon Vanveggel's work include HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (32 papers) and HIV/AIDS Research and Interventions (23 papers). Simon Vanveggel is often cited by papers focused on HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (32 papers) and HIV/AIDS Research and Interventions (23 papers). Simon Vanveggel collaborates with scholars based in Belgium, United States and United Kingdom. Simon Vanveggel's co-authors include Katia Boven, L Rimsky, Herta Crauwels, Jean‐Michel Molina, Beatriz Grinsztejn, Anthony Mills, Calvin Cohen, Kiat Ruxrungtham, Jan Fourie and Bonaventura Clotet and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Simon Vanveggel

42 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Vanveggel Belgium	21	1.5k	1.1k	370	302	179	43	1.8k
Herta Crauwels Belgium	22	1.5k 1.0×	1.1k 0.9×	292 0.8×	304 1.0×	83 0.5×	59	1.9k
Patricia W. H. Hugen Netherlands	19	973 0.7×	733 0.6×	163 0.4×	177 0.6×	35 0.2×	27	1.1k
Ana Milinkovic Spain	25	1.4k 0.9×	771 0.7×	890 2.4×	818 2.7×	28 0.2×	70	2.3k
Richard Elion United States	21	1.5k 1.0×	826 0.7×	438 1.2×	562 1.9×	9 0.1×	46	1.8k
Renate Strehlau South Africa	21	800 0.5×	515 0.5×	369 1.0×	177 0.6×	23 0.1×	84	1.2k
Jean van Wyk United Kingdom	18	930 0.6×	608 0.5×	345 0.9×	265 0.9×	9 0.1×	58	1.2k
Douglas Kitch United States	21	994 0.7×	678 0.6×	1.2k 3.3×	288 1.0×	10 0.1×	38	1.8k
S. Herrmann Australia	16	436 0.3×	308 0.3×	427 1.2×	259 0.9×	21 0.1×	40	997
Neil Buss Switzerland	13	375 0.3×	252 0.2×	71 0.2×	130 0.4×	50 0.3×	17	655
Nils von Hentig Germany	19	369 0.2×	243 0.2×	155 0.4×	167 0.6×	28 0.2×	41	981

Countries citing papers authored by Simon Vanveggel

Since Specialization

Citations

This map shows the geographic impact of Simon Vanveggel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Vanveggel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Vanveggel more than expected).

Fields of papers citing papers by Simon Vanveggel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Vanveggel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Vanveggel. The network helps show where Simon Vanveggel may publish in the future.

Co-authorship network of co-authors of Simon Vanveggel

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Vanveggel. A scholar is included among the top collaborators of Simon Vanveggel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Vanveggel. Simon Vanveggel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ariyawansa, Jay, et al.. (2023). Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study. Clinical Pharmacology in Drug Development. 12(11). 1060–1068. 2 indexed citations

Chounta, Vasiliki, Edgar T. Overton, Anthony Mills, et al.. (2021). Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 14(6). 849–862. 47 indexed citations

MacBrayne, Christine E., Richard M. Rutstein, Andrew Wiznia, et al.. (2021). Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 35(9). 1413–1421. 2 indexed citations

Eron, Joseph J., Chloe Orkin, Joel E. Gallant, et al.. (2018). A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 32(11). 1431–1442. 67 indexed citations

Opsomer, Magda, Dessislava I. Dimitrova, Simon Vanveggel, et al.. (2018). Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir. Drugs in R&D. 18(3). 199–210. 9 indexed citations

Crauwels, Herta, et al.. (2018). Bioequivalence of the Once‐Daily Single‐Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability. Clinical Pharmacology in Drug Development. 8(4). 480–491. 7 indexed citations

Green, Bruce, et al.. (2016). Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine. Clinical Pharmacokinetics. 56(5). 525–536. 8 indexed citations

Sanden, Suzy Van, et al.. (2014). Non-Inferiority of Once-Daily Cobicistat-Boosted Darunavir Versus Ritonavir-Boosted Darunavir in Hiv-1-infected Adult Patients: An Adjusted Comparative Analysis of Pooled Phase 3 Data. Value in Health. 17(7). A664–A664. 2 indexed citations

Behrens, Georg M. N., Bart Rijnders, Mark Nelson, et al.. (2014). Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care and STDs. 28(4). 168–175. 23 indexed citations

10.

Arathoon, Eduardo, As’ad E. Bhorat, Herta Crauwels, et al.. (2014). Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV‐1‐infected treatment‐experienced adults. Journal of the International AIDS Society. 17(4S3). 19783–19783. 2 indexed citations

11.

Nelson, Mark, Richard Elion, C Cohen, et al.. (2013). Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies. HIV Clinical Trials. 14(3). 81–91. 46 indexed citations

12.

Wohl, David A., Chloe Orkin, Manuela Doroana, et al.. (2013). Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo). Antiviral Therapy. 19(2). 191–200. 36 indexed citations

13.

Nelson, Mark, Nathan Clumeck, Pablo Tebas, et al.. (2012). Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. Journal of Antimicrobial Chemotherapy. 67(8). 2020–2028. 30 indexed citations

14.

Vingerhoets, Johan, L Rimsky, Veerle Van Eygen, et al.. (2012). Pre-Existing Mutations in the Rilpivirine Phase Iii Trials Echo and Thrive: Prevalence and Impact on Virological Response. Antiviral Therapy. 18(2). 253–256. 31 indexed citations

15.

Wilkin, Aimee, Anton Pozniak, Javier O Morales-Ramirez, et al.. (2011). Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase IIb Randomized Trial. AIDS Research and Human Retroviruses. 28(5). 437–446. 45 indexed citations

16.

Cohen, Calvin, Jaime Andrade‐Villanueva, Bonaventura Clotet, et al.. (2011). Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. The Lancet. 378(9787). 229–237. 286 indexed citations

17.

Cohen, Calvin, Jean‐Michel Molina, Isabel Cassetti, et al.. (2011). Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults. 13 indexed citations

18.

Molina, Jean‐Michel, Pedro Cahn, Beatriz Grinsztejn, et al.. (2011). Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. The Lancet. 378(9787). 238–246. 315 indexed citations

19.

Vanveggel, Simon. (2009). TMC278 25mg qd Has No Effect on Corrected QT (QTc) Interval in HIV-Negative Volunteers. 3 indexed citations

20.

Pozniak, Anton, Javier O Morales-Ramirez, Elly Katabira, et al.. (2009). Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 24(1). 55–65. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact